BlueSkinX

We are trying to combine human expertise and AI to dig deep into textbooks and paper piles of dermatology, especially information related to COVID-19. Our technology measures a risk based on data collected on skin of patients and support doctors to review conditions remotely.

This is an attempt of incorporating pre-existing knowledge and observations systematically. We will try to use NLP to dig deep in textbooks and paper piles, especially about COVID-19 to find persistent narratives.

After 6 months, there are nearly 8 million of people getting infected by COVID-19 in more than 210 countries and territories around the world. New data shows that syndrome could be detected by naked eyes. 

Particularly, those are lesions, rashes or discolored skin of fingers or toes which are officially added to WHO site as a correlated syndrome (rare cases), especially associated with asymptomatic cases (negative test results with/ without internal injury)

Asymptomatic cases of COVID-19 is super hard to detect. Most are seen in children and young population with no indication, e.g. negative antibody tests. Very little data could be collected by contact tracing methodology. In addition, it is 3-10x more expensive to technically examine internal injury with no clear impact. 

We are trying to combine human expertise and AI to dig deep into textbooks and paper piles of dermatology, especially information related to COVID-19. Our technology measures a risk based on data collected on skin of patients and support doctors to review conditions remotely.

This is an attempt of incorporating pre-existing knowledge and observations systematically. We will try to use NLP to dig deep in textbooks and paper piles, especially about COVID-19 to find persistent narratives.

Tentatively, the first pilot will be conducted within Switzerland, especially in the Alps. The population has a high risk of severe skin diseases with specific needs. We established business relationship one year ago during an international idea-stage challenge. Now we are coming up with a full solution and see how it fits to the workflow.

Detecting asymptomatic cases is a new area of research of COVID-19. So far, most of effort has been invested to pre-symptomatic and symptomatic cases with specific evidences for establishing knowledge. 

The solution we propose in the Challenge is now more like a hypothesis about a correlation between syndrome on skin and asymptomatic cases. Our current effort in is securely collecting more data to strengthen the statement, thus allows more further investigation and accelerate learning progress of medical community by using AI.

• Unexpected occurrences: Our motivation at the beginning was to create a non-profit project. It serves as a tool for the climate change community in order to close a gap in communication with the public audience that would be based on a story of personal health.
• Incongurities: The proposal is still assumption-based solution based on very little data confirmed by conventional practices of medical communities.  We believe data-drive technology plays an critical role to magnify an impact in an effort to combat the pandemic.
• Needs: Detect asymptomatic cases which could not be found or very little by contact tracing methodology. Allow patient to share data with doctors remotely.
• Industry and market changes: Most of competitors are focused on beauty care. We started with skin cancer detection, especially residents of Caucasian background living in high altitudes and low ambient environments. We launched BlueSkin last year and re-launched in May with a new value prop directed to COVID-19, which we believe is more urgent and impactful at this time.
• Demographic changes: A global story of number of asymptomatic cases in infants and young population.
• Changes of perception: Skin is an early sign of personal health which can be seen by naked eyes.
• Bring new knowledge: Provide more insights to understand COVID-19.

There are three main core technologies are here.

• Privacy technology enable data sharing with GDPR and HIPAA backed by AWS and Segment.
• Mobile phone technology on Android backed by Google Cloud.
• AI technology is a combination of state-of-the-art in research community in Natural Language Processing and Computer Vision through collaboration with top institutions in the US and Switzerland.

• AWS GDPR https://aws.amazon.com/compliance/gdpr-center/
• AWS HIPAA: https://d1.awsstatic.com/whitepapers/compliance/AWS_HIPAA_Compliance_Whitepaper.pdf
• Segment: https://segment.com/product/gdpr/
• AI with Natural Language Processing: COVIDEX: https://covidex.ai/
• AI with computer vision: https://www.kaggle.com/c/siim-isic-melanoma-classification

• In the short term, we are working with academia to bring AI into the Dermatology community. 
  

• In the long term, we hope our technology will serve as a propeller to facilitate more innovation in the medical community, especially in the context of COVID-19. 

• And for doctors, our goal is to serve as a support system that organizes information in a faster, more comprehensive way to improve timely and accurate diagnostic information, which advances patient outcomes.
• We want to empower users to take control of their health by giving them tools they need to understand their bodies and to be able to take action to mitigate diseases and health risks at an early stage. 
• Our vision for BlueSkin is to provide an intelligent support service for patients and healthcare providers that prioritizes the well-being of individuals and addresses the role the environment plays in our health. 

The solution is in development mode. Our pilot will be taken place starting from this August.

During a pandemic, physical interaction is a threat to public health and communities. The system tends to be overwhelmed because a lack of systematical fast response to deal with a surge. In addition, healthcare workers are vulnerable when exposing to patients regardless diseases.

BlueSkin is ZenDesk for Healthcare System. We works with health providers and their customers to transform experience into the digital world holistically. Our current model is subscription based on need of doctors, clinics and hospitals.

Our path is a combination of grant funding, selling a product and raising investment capital as a tech startup followed model of Silicon Valley.

We don't really have a high expectation when joining Solve. Here is more like an opportunity for us to refine ideas and find resources to build up a better solutions.

We are seeking partnership in healthcare industry to start pilot projects and/or bring our product into the market as soon as possible.